SEARCH

SEARCH BY CITATION

References

  • Ansell, S.M., Byrd, J.C., Horwitz, S.M., Borchmann, P., Engert, A., Strair, R., Khan, K., Fischkoff, S.A. & Yellin, M. (2004) Phase I/II open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma [abstract]. Blood, 104, 2636a.
  • Carretero-Margolis, C.D. & Fivenson, D.P. (2003) A complete and durable response to denileukin diftitox in a patient with mycosis fungoides. Journal of the American Academy of Dermatology, 48, 275276.
  • Coiffier, B., Brousse, N., Peuchmaur, M., Berger, F., Gisselbrecht, C., Bryon, P.A. & Diebold, J. (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Annals of Oncology, 1, 4550.
  • Czuczman, M.S., Porcu, P., Johnson, J., Niedzwiecki, D., Canellos, G. & Cheson, B.D. (2004) CALGB 59901: results of a phase II study of 506U78 in CTCL and PTCL [abstract]. Blood, 104, 2486a.
  • Dang, N., Hagemeister, F., Duvic, M., Romaguera, J., Younes, A., Jones, D., Samuels, B., Fayad, L., Pro, B., Samaniego, F., Sarris, A., Goy, A., McLaughlin, P., Tong, A.T., Walker, P.L., Tiongson, L.P., Smith, T.L., Huh, Y.O., Morimoto, C. & Rodriguez, M.A. (2003) Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncology Reports, 10, 15131518.
  • Dang, N.H., Hagemeister, F.B., Pro, B., McLaughlin, P., Romaguera, J.E., Jones, D., Samuels, B., Samaniego, F., Younes, A., Wang, M., Goy, A., Rodriguez, M.A., Walker, P.L., Arredondo, Y., Tong, A.T. & Fayad, L. (2004) Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 22, 40954102.
  • Dearden, C.E. & Foss, F.M. (2003) Peripheral T-cell lymphomas: diagnosis and management. Hematology Oncology Clinics of North America, 217, 13511366.
  • Duvic, M., Cather, J., Maize, J. & Frankel, A.E. (1998) DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. American Journal of Hematology, 58, 8790.
  • Economopoulos, T., Papageorgiou, S., Dimopoulos, M.A., Pavlidis, N., Tsatalas, C., Symeonidis, A., Foudoulakis, A, Pectasides, D., Rontogianni, D., Rizos, E., Chalkia, P., Anagnostopoulos, A., Melachrinou, M., Papageorgiou, E. & Fountzilaset, G. (2005) Non-Hodgkin's lymphomas in Greece according to WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. Acta Haematologica, 113, 97103.
  • Enblad, G. Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. & Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 29202924.
  • Escalón, M.P., Liu, N.S., Yang, Y., Hess, M., Walker, P.L., Smith, T.L. & Dang, N.H. (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer, 103, 20912098.
  • Forero-Torres, A., Bernstein, S., Gopal, A., Foss, F., Leonard, J., Rosenblatt, J., Bartlett, N., Younes, A., Fisher, D., Cheson, B., Carabasi, M., Bociek, G., Hart, B. & McDonald, M. (2004) SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma [abstract]. Blood, 104, 2637a.
  • Foss, F.M. (2000) DAB389IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clinical Lymphoma, 1, 110116.
  • Foss, F.M. (2001) Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Annals of the New York Academy of Sciences, 941, 166176.
  • Foss, F.M., Borkowski, T.A., Gilliom, M., Stetler-Stevenson, M., Jaffe, E.S., Figg, W.D., Tompkins, A., Bastian, A., Nylen, P. & Woodworth, T. (1994) Chimeric fusion protein toxin DAB486 IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood, 84, 17651774.
  • Frankel, A.E., Fleming, D.R., Hall, P.D., Powell, B.L., Black, J.H., Leftwich, C. & Gartenhaus, R. (2003) A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clinical Cancer Research, 9, 35553561.
  • Gisselbrecht, C., Gaulard, P., Lepage, E., Coiffier, B., Briere, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, H., Berger, F., Bouhabdallah, R. & Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood, 92, 7682.
  • Jantunen, E. & D'Amore, F. (2004) Stem cell transplantation for peripheral T-cell lymphomas. Leukemia & Lymphoma, 45, 441446.
  • LeMaistre, C.F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T. & Parkinson, D.R. (1992) Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79, 25472554.
  • Melnyk, A., Rodriguez, A., Pugh, W.C. & Cabannillas, F. (1997) Evaluation of the revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood, 89, 45144520.
  • Monfardini, S., Sorio, R., Cavalli, F., Cerny, TH., Van Glabbeke, M., Kaye, S. & Smyth, J.F. (1996) Pentostatin (2’-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC early clinical trials group. Oncology, 53, 153168.
  • Nakase, K., Kita, K., Nasu, K., Ueda, T., Tanaka, I., Shirakawa, S. & Tsudo, M. (1994) Differential expression of interleukin-2 receptors (α and β chain) in mature lymphoid malignancies. American Journal of Hematology, 46, 179183.
  • Nichols, J., Foss, F., Kuzel, T.M., LeMaistre, C.F., Platanias, L., Ratain, M.J., Rook, A., Saleh, M. & Schwartz, G. (1997) Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. European Journal of Cancer, 33(Suppl. 1), S34S36.
  • Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glade, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P. & Nichols, J. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology, 19, 376388.
  • Piekarz, R.L., Frye, R., Turner, M., Wright, J., Leonard, J., Allen, S., Smith, S., Kischbaum, M., Zain, J. & Bates, S.E. (2005) Responses and molecular markers in patient with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228. Proceedings of the American Society of Clinical Oncology, 24, 3061a.
  • Re, G.G., Waters, C., Poisson, L., Willingham, M.C., Sugamura, K. & Frankel, A.E. (1996) Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured human hematopoietic cells. Cancer Research, 56, 25902595.
  • Rodriguez, J., Munsell, M., Yazji, S., Hagemeister, F.B., Younes, A., Andersson, B., Giralt, S., Gajewski, J., De Lima M., Couriel, D., Romaguera, J., Cabanillas, F.F., Champlin, R.E. & Khouri, I.F. (2001) Impact of high-dose chemotherapy on peripheral T-cell lymphomas. Journal of Clinical Oncology, 19, 37663770.
  • Rosolen, A., Nakanishi, M., Poplack, D.G., Cole, D., Quinones, R., Reaman, G., Trepel, J.B., Cotelingam, J.D., Sausville, E.A. & Marti, G.E. (1989) Expression of interleukin-2 receptor β subunit in hematopoietic malignancies. Blood, 73, 19681972.
  • Saleh, M.N., LeMaistre, C.F., Kuzel, T.M., Foss, F., Platanias, L.C., Schwartz, G., Ratain, M., Rook, A., Freytes, C.O., Craig, F., Reuben, J., Sams, M.W. & Nichols, J.C. (1998) Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. Journal of the American Academy of Dermatology, 39, 6373.
  • Sallah, S., Wan, J.Y. & Nguyen, N.P. (2001) Treatment of refractory T-cell malignancies using gemcitabine. British Journal of Haematology, 113, 185187.
  • Talpur, R., Apisarnthanarax, N., Ward, S. & Duvic, M. (2002) Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK®). Leukemia & Lymphoma, 43, 121126.
  • Taniguchi, T. & Minami, Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell, 73, 58.
  • Tsimberidou, A., Giles, F., Duvic, M., Fayad, L. & Kurzrock, R. (2004) Phase II study of pentostatin in advanced T-cell lymphoid malignancies. Cancer, 100, 342349.
  • Vose, J.M., Peterson, C., Bierman, P.J., Weisenburger, D.D., Linder, J., Harrington, D., Vaughan, W.P., Kessinger, A. & Armitage, J.O. (1990) Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood, 76, 424431.
  • Waldman, T.A., White, J.D., Carrasquillo, J.A., Reynolds, J.C., Paik, C.H., Gansow, O.A., Brechbiel, M.W., Jaffe, E.S., Fleisher, T.A., Goldman, C.K., Top, L.E., Bamford, R., Zaknoen, S., Roessler, E., Kasten-Sportes, C., England, R., Litou, H., Johnson, J.A., Jackson-White, T., Manns, A., Hanchard, B., Junghans, R.P. & Nelson D.L. (1995) Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 86, 40634075.
  • Zinzani, P.L., Magagnoli, M., Bendani, M., Fraternali Orcioni, G., Gherlinzoni, F., Albertini, P., Pileri, S.A. & Tura, S. (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annals of Oncology, 9, 13511353.